Angiomotin在肿瘤形成及Hippo信号通路中调控研究进展

The role of angiomotin in tumorigenesis and Hippo pathway

Angiomotin(AMOT)是一种血管抑制素结合蛋白,AMOT在血管内皮细胞的迁移、紧密连接和管状形成等方面起着重要调控作用。AMOT及其同源家族蛋白AMOTL1和AMOTL2可能与Hippo信号通路的下游效应分子YAP相互作用来参与调控肿瘤细胞的生长。在乳腺癌、前列腺癌等癌症中,AMOT能够增加YAP进入细胞核的水平从而促进癌细胞的增殖和迁移;但在胶质母细胞瘤、肺癌等癌细胞中,AMOT将YAP滞留在细胞质或紧密连接处,从而抑制YAP的活性。另外,AMOT也可以促进Hippo信号通路中核心激酶LATS来发挥抑制肿瘤细胞增殖的作用。AMOT在肿瘤细胞生长中发挥的不同作用还需要更深入的研究,现对AMOT在癌症中的调控作用及在Hippo信号通路中的调控机制等方面的研究进展进行综述。

Angiomotin(AMOT) identified as angiostatin binding protein, and it plays an important role in the regulation of endothelial cell migration, tight junction and blood vessel formation. AMOT and its homologues AMOTL1 and AMOTL2 may interact with YAP, a downstream effector of Hippo pathway, to regulate the growth of tumor cells. AMOT could increase the level of YAP into the nucleus to promote the proliferation and progression of cancer cells such as breast cancer, prostate cancer. On the other hands, AMOT could delay YAP into the cytoplasm which could inhibits the growth of tumor cells such as glioblastoma and lung cancer. In addition, AMOT can also promote the core kinase LATS in Hippo pathway to inhibit the proliferation of tumor cells. The different roles of AMOT in the growth of tumor cells need to be further studied. This article mainly reviews the research progress in the regulation of AMOT in cancer and the regulation mechanism of Hippo pathway in cancer.